Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

PACB Pacific Biosciences Of California Inc

Price (delayed)

$0.9415

Market cap

$282.53M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.28

Enterprise value

$922.44M

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
The debt is down by 25% year-on-year but it is up by 4% since the previous quarter
PACB's net income has shrunk by 122% YoY and by 112% QoQ
The EPS has plunged by 102% from the previous quarter and by 100% YoY

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
300.08M
Market cap
$282.53M
Enterprise value
$922.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.06
Price to sales (P/S)
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
Earnings
Revenue
$152.36M
Gross profit
$24.63M
Operating income
-$841.37M
Net income
-$657.75M
EBIT
-$646.16M
EBITDA
-$232.04M
Free cash flow
-$178.13M
Per share
EPS
-$2.28
EPS diluted
-$2.74
Free cash flow per share
-$0.6
Book value per share
$0.31
Revenue per share
$0.51
TBVPS
$1.77
Balance sheet
Total assets
$860.79M
Total liabilities
$769.15M
Debt
$699.11M
Equity
$91.64M
Working capital
$378.32M
Liquidity
Debt to equity
7.63
Current ratio
6.68
Quick ratio
5.64
Net debt/EBITDA
-2.76
Margins
EBITDA margin
-152.3%
Gross margin
16.2%
Net margin
-431.7%
Operating margin
-552.2%
Efficiency
Return on assets
-51.8%
Return on equity
-170.4%
Return on invested capital
-51%
Return on capital employed
-81.4%
Return on sales
-424.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-4.05%
1 week
-11.18%
1 month
-19.53%
1 year
-49.11%
YTD
-48.55%
QTD
-20.21%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$152.36M
Gross profit
$24.63M
Operating income
-$841.37M
Net income
-$657.75M
Gross margin
16.2%
Net margin
-431.7%
PACB financials
The net margin has dropped by 191% year-on-year and by 115% since the previous quarter
The company's operating income has shrunk by 161% YoY and by 77% QoQ
PACB's net income has shrunk by 122% YoY and by 112% QoQ
PACB's operating margin has dropped by 79% since the previous quarter

Price vs fundamentals

How does PACB's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Price vs fair value

Growth

What is Pacific Biosciences Of California's growth rate over time
PACB growth chart

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
3.06
P/S
1.83
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.05
Valuation vs average
Price to earnings (P/E)
The EPS has plunged by 102% from the previous quarter and by 100% YoY
Price to book (P/B)
The company's equity has shrunk by 86% YoY and by 82% QoQ
The P/B is 80% above the last 4 quarters average of 1.7 but 54% below the 5-year quarterly average of 6.7
Price to sales (P/S)
The price to sales (P/S) is 91% lower than the 5-year quarterly average of 21.1 and 30% lower than the last 4 quarters average of 2.6
The revenue has decreased by 24% YoY

Efficiency

How efficient is Pacific Biosciences Of California business performance
The ROE has plunged by 189% from the previous quarter
The ROS has plunged by 189% YoY and by 121% from the previous quarter
The company's return on invested capital has shrunk by 154% YoY and by 137% QoQ
PACB's ROA has plunged by 147% from the previous quarter

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
Assets vs liabilities
The company's total assets is 12% higher than its total liabilities
The company's total assets fell by 48% YoY and by 32% QoQ
The quick ratio has contracted by 31% YoY and by 11% from the previous quarter
Debt vs equity
The company's equity has shrunk by 86% YoY and by 82% QoQ
The debt is down by 25% year-on-year but it is up by 4% since the previous quarter
Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.